NEW YORK (GenomeWeb News) – Foundation Medicine has filed with the US Securities and Exchange Commission to sell up to $150 million of its common stock in a public offering.

In a Form S-1 filed with the SEC on Thursday, the Cambridge, Mass.-based firm said the "purpose of this offering is to increase our financial flexibility," and proceeds will be used to accelerate its commercial operations and R&D, as well as to expand its technology infrastructure and technology platform, and to fund ongoing and new clinical trials.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.